Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 12/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | DRD4 | P21917 | 3/20 | 0.34 |
| ▸ | HPN | P05981 | 1/20 | 0.34 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.34 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25016759 | 0.87 | F2 (0.42) | CNR2F10LIPGF2PRSS1 | |
| SCHEMBL25016132 | 0.85 | CNR2 (0.40) | CNR2F10ITGB3ITGA2BLIPG | |
| SCHEMBL25017307 | 0.80 | F10 (0.49) | F10ITGB3ITGA2BF2PRSS1 | |
| SCHEMBL25016737 | 0.80 | PRSS1 (0.45) | F10ITGB3ITGA2BF2PRSS1 | |
| SCHEMBL25016131 | 0.80 | PRSS1 (0.45) | F10ITGB3ITGA2BF2PRSS1 | |
| SCHEMBL25017315 | 0.79 | F10 (0.45) | F10ITGB3ITGA2BF2PRSS1 | |
| SCHEMBL25017834 | 0.79 | ST14 (0.45) | CNR2F10ITGB3ITGA2BF2 | |
| SCHEMBL25015687 | 0.79 | ACSS2 (0.42) | F10ITGB3ITGA2BF2PRSS1 | |
| SCHEMBL25015686 | 0.78 | PLAU (0.45) | CNR2F10F2PRSS1 | |
| SCHEMBL25016289 | 0.77 | F10 (0.39) | F10F2PRSS1HPNHGFAC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | CNR2 4734/4885F10 1548/4885ITGB3 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.